ZA92302B - Optically active 5h-pyrrolo-(3,4-b)pyrazine derivative,its preparation and pharmaceutical compositions containing it - Google Patents

Optically active 5h-pyrrolo-(3,4-b)pyrazine derivative,its preparation and pharmaceutical compositions containing it

Info

Publication number
ZA92302B
ZA92302B ZA92302A ZA92302A ZA92302B ZA 92302 B ZA92302 B ZA 92302B ZA 92302 A ZA92302 A ZA 92302A ZA 92302 A ZA92302 A ZA 92302A ZA 92302 B ZA92302 B ZA 92302B
Authority
ZA
South Africa
Prior art keywords
pyrrolo
preparation
pharmaceutical compositions
optically active
compositions containing
Prior art date
Application number
ZA92302A
Other languages
English (en)
Inventor
Claude Cotrel
Cotrel Claude
Gerard Roussel
Roussel Gerard
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9408772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA92302(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA92302B publication Critical patent/ZA92302B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA92302A 1991-01-17 1992-01-15 Optically active 5h-pyrrolo-(3,4-b)pyrazine derivative,its preparation and pharmaceutical compositions containing it ZA92302B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9100490A FR2671800B1 (fr) 1991-01-17 1991-01-17 Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.

Publications (1)

Publication Number Publication Date
ZA92302B true ZA92302B (en) 1992-10-28

Family

ID=9408772

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA92302A ZA92302B (en) 1991-01-17 1992-01-15 Optically active 5h-pyrrolo-(3,4-b)pyrazine derivative,its preparation and pharmaceutical compositions containing it

Country Status (29)

Country Link
US (5) US6319926B1 (de)
EP (2) EP0609210B1 (de)
JP (1) JPH06504548A (de)
AR (1) AR248024A1 (de)
AT (1) ATE121089T1 (de)
AU (2) AU671797B2 (de)
CA (1) CA2099782C (de)
CZ (1) CZ281011B6 (de)
DE (1) DE69202060T2 (de)
DK (1) DK0609210T3 (de)
ES (1) ES2071486T3 (de)
FI (1) FI100331B (de)
FR (1) FR2671800B1 (de)
HU (1) HU218928B (de)
IE (1) IE66110B1 (de)
IL (1) IL100677A (de)
MA (1) MA22392A1 (de)
MX (1) MX9200180A (de)
NO (1) NO179911C (de)
NZ (1) NZ241313A (de)
OA (1) OA09807A (de)
PH (1) PH30982A (de)
PL (1) PL166976B1 (de)
RU (1) RU2110519C1 (de)
SK (1) SK279060B6 (de)
TN (1) TNSN92004A1 (de)
WO (1) WO1992012980A1 (de)
YU (1) YU48878B (de)
ZA (1) ZA92302B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
ES2101653B1 (es) * 1995-07-10 1998-04-01 Asturpharma S A (+)-6-(5-cloropirid-2-il)-7-oxo-viniloxicarboniloxi-5,6-dihidropirrolo(3,4b)pirazina y su uso para un procedimiento de preparacion de (+)-6-(5-cloropirid-2-il)-5-(4-metilpiperazin-1-il)-carboniloxi-7-oxo-5,6-dihidropirrolo(3,4b)pirazina.
US6339086B1 (en) * 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
TW200734460A (en) 1999-10-04 2007-09-16 Ajinomoto Kk Genes for heat resistant enzymes of amino acid biosynthetic pathway derived from thermophilic coryneform bacteria
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
ES2337700T3 (es) * 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
US7776858B2 (en) 2004-04-05 2010-08-17 Sepracor Inc. Methods of treatment of chronic pain using eszopiclone
WO2006136866A1 (en) * 2005-06-21 2006-12-28 Generics [Uk] Limited Process for enantiomeric separation of zopiclone
US20080293726A1 (en) 2005-07-06 2008-11-27 Sepracor Inc. Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7863273B2 (en) * 2006-01-17 2011-01-04 Glenmark Generics Ltd. Process for the preparation of an optically active 5H-pyrrolo [3,4-B] pyrazine derivative
AR059296A1 (es) * 2006-02-03 2008-03-26 Synthon Bv Compuesto de l-tartrato de s-zopiclona y proceso para resolver los enantiomeros de zopiclona.
US20080027223A1 (en) * 2006-03-23 2008-01-31 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
US20070270590A1 (en) * 2006-04-20 2007-11-22 Marioara Mendelovici Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
EP1904499A1 (de) * 2006-06-26 2008-04-02 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von zopiclon
US7786304B2 (en) * 2006-11-06 2010-08-31 Centaur Pharmaceutical Pvt. Ltd. Process for the preparation of eszopiclone
TW200846340A (en) * 2007-01-31 2008-12-01 Teva Pharma Methods for preparing eszopiclone
ATE515259T1 (de) * 2007-05-29 2011-07-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit eszopiclon
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
TW200918534A (en) * 2007-06-25 2009-05-01 Teva Pharma Racemization process of R-zopiclone
EP2020403A1 (de) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Verfahren zur Auflösung von Zopiclon und Zwischenprodukten
US20090198058A1 (en) * 2007-08-06 2009-08-06 Dhananjay Govind Sathe Process for Preparation of Dextrorotatory Isomer of 6-(5- chloro-pyrid-2-yl)-5-[(4-methyl -1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine (Eszopiclone)
US8198278B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2747000C (en) * 2007-12-19 2013-09-03 Sunovion Pharmaceuticals Inc. Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US20110053945A1 (en) * 2007-12-19 2011-03-03 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2009101634A2 (en) * 2008-02-13 2009-08-20 Lupin Limited A novel process for the preparation of eszopiclone
WO2009114740A2 (en) * 2008-03-12 2009-09-17 Emory University USE OF GABAa RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS
US20090269409A1 (en) * 2008-04-24 2009-10-29 Mukesh Kumar Garg Pharmaceutical compositions comprising eszopiclone
CN101607961B (zh) * 2008-06-18 2011-08-10 天津天士力集团有限公司 一种右佐匹克隆结晶及其组合物
KR20110086723A (ko) 2008-11-07 2011-07-29 시플라 리미티드 조피클론을 광학분할하는 방법
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CA2750059C (en) 2009-01-30 2014-11-18 Sunovion Pharmaceuticals Inc. Coated tablets of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine and methods for measuring effectiveness of coating
WO2010116385A2 (en) 2009-04-08 2010-10-14 Rubicon Research Private Limited Pharmaceutical compositions for alleviating unpleasant taste
EP2345654A1 (de) 2010-01-05 2011-07-20 LEK Pharmaceuticals d.d. Eszopiclon-Teilchen und Verfahren zu deren Herstellung
EP2345655A1 (de) 2010-01-05 2011-07-20 LEK Pharmaceuticals d.d. Verfahren zur Racemisierung von 6-(5-Chlorpyridin-2-yl)-7-(4-methyl-1-piperazinyl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin
CN103193779B (zh) * 2012-01-05 2016-04-20 成都弘达药业有限公司 一种右佐匹克隆的制备方法
CN105007899A (zh) * 2012-12-20 2015-10-28 卡希夫制药有限责任公司 用于提高生物利用度的口腔崩解片制剂
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
JP2020007252A (ja) * 2018-07-05 2020-01-16 アクティブファーマ株式会社 エスゾピクロンジベンゾイル−ｄ−酒石酸塩の製造方法、エスゾピクロンの製造方法、及びエスゾピクロンジベンゾイル−ｄ−酒石酸塩の結晶

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA04285A (fr) * 1972-01-07 1979-12-31 Rhone Poulenc Sa Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation.
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4962124A (en) 1987-11-17 1990-10-09 Analgesic Associates Onset-hastened/enhanced antipyretic response
US4868214A (en) 1987-11-17 1989-09-19 Analgesic Associates Onset-hastened/enhanced analgesia
US5102890A (en) 1989-09-05 1992-04-07 Rhone-Poulenc Sante Pyrrole derivatives, their preparation and pharmaceutical compositions which contain them
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
WO1993010788A1 (en) 1991-12-02 1993-06-10 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
US5331000A (en) 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US6436926B1 (en) * 1999-05-10 2002-08-20 Medpointe, Inc. Compositions and methods for treating superficial fungal infections
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
AR059296A1 (es) * 2006-02-03 2008-03-26 Synthon Bv Compuesto de l-tartrato de s-zopiclona y proceso para resolver los enantiomeros de zopiclona.

Also Published As

Publication number Publication date
HU218928B (hu) 2000-12-28
HUT68915A (en) 1995-08-28
US20020193378A1 (en) 2002-12-19
EP0495717A1 (de) 1992-07-22
FR2671800B1 (fr) 1993-03-12
FI933248A (fi) 1993-07-16
ATE121089T1 (de) 1995-04-15
US20060194806A1 (en) 2006-08-31
CA2099782A1 (fr) 1992-07-18
AU1226492A (en) 1992-08-27
AU3032195A (en) 1995-11-09
US6319926B1 (en) 2001-11-20
US6444673B1 (en) 2002-09-03
YU5592A (sh) 1994-11-15
IL100677A (en) 1995-11-27
US7381724B2 (en) 2008-06-03
SK71993A3 (en) 1993-12-08
MA22392A1 (fr) 1992-10-01
HU9302063D0 (en) 1993-10-28
EP0609210B1 (de) 1995-04-12
PL166976B1 (pl) 1995-07-31
NO179911C (no) 1997-01-08
CZ281011B6 (cs) 1996-05-15
US7125874B2 (en) 2006-10-24
DE69202060T2 (de) 1995-10-26
NO931919D0 (no) 1993-05-26
SK279060B6 (sk) 1998-06-03
EP0609210A4 (de) 1993-09-17
AR248024A1 (es) 1995-05-31
DE69202060D1 (de) 1995-05-18
AU671797B2 (en) 1996-09-12
CZ138093A3 (en) 1994-02-16
MX9200180A (es) 1992-07-01
NO179911B (no) 1996-09-30
US20050043311A1 (en) 2005-02-24
RU2110519C1 (ru) 1998-05-10
NZ241313A (en) 1993-03-26
IE920126A1 (en) 1992-07-29
EP0609210A1 (de) 1994-08-10
IL100677A0 (en) 1992-09-06
PH30982A (en) 1997-12-23
US6864257B2 (en) 2005-03-08
YU48878B (sh) 2002-09-19
CA2099782C (fr) 2002-12-03
WO1992012980A1 (fr) 1992-08-06
JPH06504548A (ja) 1994-05-26
DK0609210T3 (da) 1995-07-03
FI933248A0 (fi) 1993-07-16
ES2071486T3 (es) 1995-06-16
TNSN92004A1 (fr) 1993-06-08
OA09807A (fr) 1994-04-15
FI100331B (fi) 1997-11-14
NO931919L (no) 1993-05-26
FR2671800A1 (fr) 1992-07-24
IE66110B1 (en) 1995-12-13

Similar Documents

Publication Publication Date Title
ZA92302B (en) Optically active 5h-pyrrolo-(3,4-b)pyrazine derivative,its preparation and pharmaceutical compositions containing it
SG55163A1 (en) Pharmaceutical formulations
IL101864A0 (en) Thiopyranopyrrole derivatives,their preparation and pharmaceutical compositions containing them
IL102777A0 (en) Pharmaceutical combination formulation
NZ232168A (en) Perhydropyrido(1,2-a)pyrazine derivatives; intermediates and pharmaceutical compositions
IL102261A0 (en) 7-isoindolinyl-quinolone-and-naphthyridonecarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL103160A0 (en) Quinoxaline compounds,their preparation and pharmaceutical compositions containing them
IL103292A0 (en) Cyclic-substituted imidazolyl-propenoic acid derivatives,their preparation and pharmaceutical compositions containing them
GB9114950D0 (en) Pharmaceutical formulation
GB9103302D0 (en) Pharmaceutical formulations
HU9303113D0 (en) Pharmaceutical compositions containing 1,2-dithiol-3-thione-derivatives
IL102500A0 (en) 3-deoxy-mannosamine derivatives,their preparation and pharmaceutical compositions containing them
IL103291A0 (en) Imidazolyl-propenoic acid derivatives,their preparation and pharmaceutical compositions containing them
IL99637A0 (en) 5h-benzodiazepine derivative,its preparation and pharmaceutical compositions containing it
IL105391A0 (en) 1,2,4-benzothiadiazine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL95312A0 (en) Substituted pyrazine,its preparation and pharmaceutical compositions containing it
GB9216061D0 (en) Pharmaceutical combination formulation
IL102478A0 (en) 3,4-dehydropiperidine derivatives,their preparation and pharmaceutical compositions containing them
IL103387A0 (en) Naphthoquinone derivatives,their preparation and pharmaceutical compositions containing them
GB9112974D0 (en) Pharmaceutical formulation
GB9122115D0 (en) Pharmaceutical formulation
GB9122114D0 (en) Pharmaceutical formulation
GB9121798D0 (en) Pharmaceutical formulation
GB9116467D0 (en) Pharmaceutical formulation
GB9125005D0 (en) Pharmaceutical formulations